1 Ocak 2017 Dergi makalesi Açık Erişim

Erturk, Zeliha; Buber, Esra; Ozen, Haluk; Celikbicak, Omur; Salih, Bekir; Acan, N. Leyla

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Erturk, Zeliha</dc:creator>
  <dc:creator>Buber, Esra</dc:creator>
  <dc:creator>Ozen, Haluk</dc:creator>
  <dc:creator>Celikbicak, Omur</dc:creator>
  <dc:creator>Salih, Bekir</dc:creator>
  <dc:creator>Acan, N. Leyla</dc:creator>
  <dc:date>2017-01-01</dc:date>
  <dc:description>Objective: Immunotherapy with intravesical Bacillus Calmette-Guerin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects. We aimed to develop less toxic and more powerful therapeutic agents for the treatment of bladder cancer than live strain.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/47033</dc:identifier>
  <dc:identifier>oai:zenodo.org:47033</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY 16(3) 70-76</dc:source>
  <dc:title>Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>